Contrasting Scopus BioPharma (NASDAQ:SCPS) & MorphoSys (NASDAQ:MOR)
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
Novartis: launch of Morphosys drug by could be 2027 or later
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MOR
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority Shareholders
The State of Massachusetts Issues MOR-EV Approval, Granting Mullen's Class 3 EV Truck a $15,000 Cash Voucher per Vehicle Sold
MorphoSys AG Forecasted to Post Q2 2024 Earnings of ($0.54) Per Share (NASDAQ:MOR)
Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)
MorphoSys: Hold Rating Until The Novartis Deal Closes
MorphoSys AG Reports First Quarter 2024 Financial Results
Morphosys says Novartis takeover progressing as planned for H1 2024
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Novartis begins tender offer for MorphoSys
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?
What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?
Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline
Novartis to buy cancer drug maker MorphoSys for €2.7 billion
Novartis to bolster its oncology portfolio with acquisition of MorphoSys
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Novartis acquires cancer drug developer MorphoSys for $2.9 bln
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Why Is MorphoSys (MOR) Stock Up 50% Today?
Exclusive: Novartis in the lead to acquire cancer drug developer MorphoSys-sources
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study
Why Is MorphoSys (MOR) Stock Down 20% Today?
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
MorphoSys: Buying Constellation Was A Desperate Measure
MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating)
MorphoSys AG (MOR) Q3 2023 Earnings Call Transcript
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023